BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35626131)

  • 1. Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response.
    Mulet M; Osuna-Gómez R; Zamora C; Porcel JM; Nieto JC; Perea L; Pajares V; Muñoz-Fernandez AM; Calvo N; Sorolla MA; Vidal S
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
    Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
    Cancer Lett; 2020 Oct; 491():78-86. PubMed ID: 32726613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental supporting data on the influence of platelet-derived factors of malignant pleural effusions on T cell effector functions and their relevance in predicting prognosis of lung adenocarcinoma patients with pleural metastasis.
    Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
    Data Brief; 2020 Oct; 32():106266. PubMed ID: 32984462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
    Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients.
    Nieto JC; Zamora C; Porcel JM; Mulet M; Pajares V; Muñoz-Fernandez AM; Calvo N; Espinosa I; Pascual-García M; Bielsa S; Vidal S
    Sci Rep; 2019 Feb; 9(1):2996. PubMed ID: 30816121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions.
    Xu P; Tang K; Ma J; Zhang H; Wang D; Zhu L; Chen J; Wei K; Liu J; Fang H; Tang L; Zhang Y; Xie J; Liu Y; Meng R; Liu L; Dong X; Yang K; Wu G; Ma F; Huang B
    Cancer Immunol Res; 2020 Sep; 8(9):1193-1205. PubMed ID: 32661094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
    Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis.
    Hung TL; Chen FF; Liu JM; Lai WW; Hsiao AL; Huang WT; Chen HH; Su WC
    Clin Cancer Res; 2003 Jul; 9(7):2605-12. PubMed ID: 12855637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the diagnosis value of carcinoembryonic antigen in malignant pleural effusion].
    Yu YX; Tong ZH; Zhou XX; Liang LR; Wang Z; Xu LL; Wang XJ; Wu YB; Li HJ; Lu Z
    Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(6):432-435. PubMed ID: 29429254
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Platelet Parameters in the Differential Diagnosis of Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Tuberculous Pleural Effusion.
    Ai L; Li J; Ye T; Wang W; Li Y
    Dis Markers; 2022; 2022():5653033. PubMed ID: 35531478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
    Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
    Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
    Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
    Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.
    Park DS; Hwang KE; Shim H; Kim BR; Choi KH; Park SH; Park SD; Jeong ET; Kim HR
    Clin Exp Metastasis; 2012 Feb; 29(2):83-9. PubMed ID: 22045227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion.
    Damianovich M; Hout Siloni G; Barshack I; Simansky DA; Kidron D; Dar E; Avivi C; Onn A
    Clin Lung Cancer; 2013 Nov; 14(6):688-98. PubMed ID: 23931900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion.
    Shin YM; Yun J; Lee OJ; Han HS; Lim SN; An JY; Lee KH; Lee KM; Choe KH
    Cancer Res Treat; 2014 Apr; 46(2):178-85. PubMed ID: 24851110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.
    Popowicz N; Cheah HM; Gregory C; Miranda A; Dick IM; Lee YCG; Creaney J
    PLoS One; 2021; 16(4):e0250628. PubMed ID: 33901252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
    BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion.
    Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P
    Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.